{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T02:46:12Z","timestamp":1792205172101,"version":"4.4.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2019,6,18]],"date-time":"2019-06-18T00:00:00Z","timestamp":1560816000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,18]],"date-time":"2019-06-18T00:00:00Z","timestamp":1560816000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol."],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1038\/s41386-019-0440-6","type":"journal-article","created":{"date-parts":[[2019,6,18]],"date-time":"2019-06-18T18:15:44Z","timestamp":1560881744000},"page":"1955-1966","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Disconnection of drug-response and placebo-response in acute-phase antipsychotic drug trials on schizophrenia? Meta-regression analysis"],"prefix":"10.1038","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4934-4352","authenticated-orcid":false,"given":"Stefan","family":"Leucht","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Chaimani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitris","family":"Mavridis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Leucht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maximilian","family":"Huhn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9863-2871","authenticated-orcid":false,"given":"Bartosz","family":"Helfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myrto","family":"Samara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5179-8321","authenticated-orcid":false,"given":"Andrea","family":"Cipriani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John R.","family":"Geddes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,6,18]]},"reference":[{"key":"440_CR1","doi-asserted-by":"publisher","first-page":"appiajp20171612","DOI":"10.1176\/appi.ajp.2017.16121358","volume":"174","author":"S Leucht","year":"2017","unstructured":"Leucht S, Leucht C, Huhn M, Chaimani A, Mavridis D, Helfer B, et al. Sixty years of placebo-controlled antipsychotic drug trials in acute schizophrenia: systematic review, bayesian meta-analysis, and meta-regression of efficacy predictors. Am J Psychiatry. 2017;174:appiajp201716121358.","journal-title":"Am J Psychiatry"},{"key":"440_CR2","unstructured":"Study 049. A 6-week, double-blind, randomized, fixed dose, parallel-group study of the efficacy and safety of three dose levels of SM-13496 (lurasidone) compared to placebo and haloperidol in patients with schizophrenia who are experiencing an acute exacerbation of symptoms. Center for drug evaluation and research. Application number 200603 Medical review(s) http:\/\/www.fgagov . 2010."},{"key":"440_CR3","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1016\/j.schres.2018.05.009","volume":"201","author":"S Leucht","year":"2018","unstructured":"Leucht S, Chaimani A, Leucht C, Huhn M, Mavridis D, Helfer B, et al. 60years of placebo-controlled antipsychotic drug trials in acute schizophrenia: Meta-regression of predictors of placebo response. Schizophr Res. 2018;201:315\u201323.","journal-title":"Schizophr Res"},{"key":"440_CR4","first-page":"53","volume":"43","author":"CH Mallinckrodt","year":"2010","unstructured":"Mallinckrodt CH, Zhang L, Prucka WR, Millen BA. Signal detection and placebo response in schizophrenia: parallels with depression. Psychopharmacol Bull. 2010;43:53\u201374.","journal-title":"Psychopharmacol Bull"},{"key":"440_CR5","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1176\/appi.ajp.2013.12030315","volume":"170","author":"O Agid","year":"2013","unstructured":"Agid O, Siu CO, Potkin SG, Kapur S, Watsky E, Vanderburg D, et al. Meta-regression analysis of placebo response in antipsychotic trials, 1970-2010. Am J Psychiatry. 2013;170:1335\u201344.","journal-title":"Am J Psychiatry"},{"key":"440_CR6","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1001\/jamapsychiatry.2014.1319","volume":"71","author":"BR Rutherford","year":"2014","unstructured":"Rutherford BR, Pott E, Tandler JM, Wall MM, Roose SP, Lieberman JA. Placebo response in antipsychotic clinical trials: a meta-analysis. JAMA psychiatry. 2014;71:1409\u201321.","journal-title":"JAMA psychiatry"},{"key":"440_CR7","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1016\/S0006-3223(00)00832-5","volume":"47","author":"I Kirsch","year":"2000","unstructured":"Kirsch I. Are drug and placebo effects in depression additive? Biol Psychiatry. 2000;47:733\u20135.","journal-title":"Biol Psychiatry"},{"key":"440_CR8","doi-asserted-by":"publisher","first-page":"e1000100","DOI":"10.1371\/journal.pmed.1000100","volume":"6","author":"A Liberati","year":"2009","unstructured":"Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med. 2009;6:e1000100.","journal-title":"PLoS Med"},{"key":"440_CR9","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1056\/NEJM199403103301006","volume":"330","author":"WT Carpenter","year":"1994","unstructured":"Carpenter WT, Buchanan RW. Schizophrenia. N Eng J Med. 1994;330:681\u201390.","journal-title":"N Eng J Med"},{"key":"440_CR10","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1016\/S0140-6736(12)60239-6","volume":"379","author":"S Leucht","year":"2012","unstructured":"Leucht S, Tardy M, Komossa K, Heres S, Kissling W, Salanti G, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2012;379:2063\u201371.","journal-title":"Lancet"},{"key":"440_CR11","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/S0140-6736(13)60733-3","volume":"382","author":"S Leucht","year":"2013","unstructured":"Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382:951\u201362.","journal-title":"Lancet"},{"key":"440_CR12","first-page":"77","volume":"1","author":"G Honigfeld","year":"1984","unstructured":"Honigfeld G. Clozapine: antipsychotic activity in treatment-resistant schizophrenics. Adv Ther. 1984;1:77\u201397.","journal-title":"Adv Ther"},{"key":"440_CR13","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1016\/j.euroneuro.2014.03.012","volume":"24","author":"MT Samara","year":"2014","unstructured":"Samara MT, Cao H, Helfer B, Davis JM, Leucht S. Chlorpromazine versus every other antipsychotic for schizophrenia: a systematic review and meta-analysis challenging the dogma of equal efficacy of antipsychotic drugs. Eur Neuropsychopharmacol: J Eur Coll Neuropsychopharmacol. 2014;24:1046\u201355.","journal-title":"Eur Neuropsychopharmacol: J Eur Coll Neuropsychopharmacol"},{"key":"440_CR14","doi-asserted-by":"publisher","first-page":"498","DOI":"10.7326\/0003-4819-157-7-201210020-00525","volume":"157","author":"L Hartling","year":"2012","unstructured":"Hartling L, Abou-Setta AM, Dursun S, Mousavi SS, Pasichnyk D, Newton AS. Antipsychotics in adults with schizophrenia: comparative effectiveness of first-generation versus second-generation medications: a systematic review and meta-analysis. Ann Intern Med. 2012;157:498\u2013511.","journal-title":"Ann Intern Med"},{"key":"440_CR15","first-page":"CD009831","volume":"1","author":"M Dold","year":"2015","unstructured":"Dold M, Samara MT, Li C, Tardy M, Leucht S. Haloperidol versus first-generation antipsychotics for the treatment of schizophrenia and other psychotic disorders. Cochrane Database Syst Rev. 2015;1:CD009831.","journal-title":"Cochrane Database Syst Rev"},{"key":"440_CR16","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1093\/schbul\/sbm152","volume":"34","author":"RP McMahon","year":"2008","unstructured":"McMahon RP, Kelly DL, Boggs DL, Li L, Hu Q, Davis JM, et al. Feasibility of reducing the duration of placebo-controlled trials in schizophrenia research. Schizophr Bull. 2008;34:292\u2013301.","journal-title":"Schizophr Bull"},{"key":"440_CR17","volume-title":"Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]","author":"JPT Higgins","year":"2011","unstructured":"Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 5.1.0 [updated March 2011]. Chichester, UK: Wiley and Sons; 2011."},{"key":"440_CR18","unstructured":"Wu TX, Li YP, Liu GJ, Bian Z, Li J, Zhang J, et al. Investigation of authenticity of \u2018claimed\u2019 randomized controlled trials (RCTs) and quality assessment of RCT reports published in China. Presented at the XIV Cochrane Colloquium, Dublin, Ireland, October 23\u201326; 2006."},{"key":"440_CR19","doi-asserted-by":"publisher","first-page":"i5396","DOI":"10.1136\/bmj.i5396","volume":"355","author":"M Woodhead","year":"2016","unstructured":"Woodhead M. 80% of China\u2019s clinical trial data are fraudulent, investigation finds. BMJ. 2016;355:i5396.","journal-title":"BMJ"},{"key":"440_CR20","volume-title":"The cochrane library","author":"CE Adams","year":"2011","unstructured":"Adams CE, Coutinho E, Davis JM, Duggan L, Essali A, Fenton M, et al. The cochrane library. Chichester, UK: John Wiley & Sons Ltd; 2011."},{"key":"440_CR21","volume-title":"Diagnosis and drug treatment of psychiatric disorders","author":"DF Klein","year":"1969","unstructured":"Klein DF, Davis JM. Diagnosis and drug treatment of psychiatric disorders. Baltimore: Williams and Wilkins; 1969."},{"key":"440_CR22","doi-asserted-by":"crossref","unstructured":"Adams CE, Awad G, Rathbone J. Chlorpromazine versus placebo for schizophrenia. Cochrane Database Syst Rev. 2007;Art. No.: CD000284.","DOI":"10.1002\/14651858.CD000284.pub2"},{"key":"440_CR23","doi-asserted-by":"crossref","unstructured":"Joy CB, Adams CE, Laurie S. Haloperidol versus placebo for schizophrenia. Cochrane Database Syst Rev. 2007;Art. No.: CD003082.","DOI":"10.1002\/14651858.CD000284.pub2"},{"key":"440_CR24","first-page":"CD009777","volume":"11","author":"X Shen","year":"2012","unstructured":"Shen X, Xia J, Adams CE. Flupenthixol versus placebo for schizophrenia. Cochrane Database Syst Rev. 2012;11:CD009777.","journal-title":"Cochrane Database Syst Rev"},{"key":"440_CR25","first-page":"CD006352","volume":"24","author":"HE Matar","year":"2007","unstructured":"Matar HE, Almerie MQ. Oral fluphenazine versus placebo for schizophrenia. Cochrane Database Syst Rev. 2007;24:CD006352.","journal-title":"Cochrane Database Syst Rev"},{"key":"440_CR26","doi-asserted-by":"crossref","unstructured":"Hartung B, Wada M, Laux G, Leucht S. Perphenazine for schizophrenia. Cochrane Database Syst Rev. 2005:CD003443.","DOI":"10.1002\/14651858.CD003443.pub2"},{"key":"440_CR27","doi-asserted-by":"crossref","unstructured":"Omori IM, Wang J. Sulpiride versus placebo for schizophrenia. Cochrane Database Syst Rev. 2009:CD007811.","DOI":"10.1002\/14651858.CD007811"},{"key":"440_CR28","first-page":"CD001944","volume":"6","author":"M Fenton","year":"2007","unstructured":"Fenton M, Rathbone J, Reilly J, Sultana A. Thioridazine for schizophrenia. Cochrane Database Syst Rev. 2007;6:CD001944.","journal-title":"Cochrane Database Syst Rev"},{"key":"440_CR29","first-page":"429","volume":"14","author":"S Leucht","year":"2009","unstructured":"Leucht S, Arbter D, Engel RR, Kissling W, Davis JM. How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. MolPsychiatry. 2009;14:429\u201347.","journal-title":"MolPsychiatry"},{"key":"440_CR30","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","volume":"13","author":"SR Kay","year":"1987","unstructured":"Kay SR, Fiszbein A. The positive and negative symptome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13:261\u201375.","journal-title":"Schizophr Bull"},{"key":"440_CR31","first-page":"790","volume":"10","author":"JE Overall","year":"1962","unstructured":"Overall JE, Gorham DR. The brief psychiatric rating scale. Psychol Rep. 1962;10:790\u2013812.","journal-title":"Psychol Rep"},{"key":"440_CR32","doi-asserted-by":"publisher","first-page":"956","DOI":"10.1016\/j.euroneuro.2012.11.004","volume":"23","author":"S Leucht","year":"2013","unstructured":"Leucht S, Rothe P, Davis JM, Engel RR. Equipercentile linking of the BPRS and the PANSS. Eur Neuropsychopharmacol: J Eur Coll Neuropsychopharmacol. 2013;23:956\u20139.","journal-title":"Eur Neuropsychopharmacol: J Eur Coll Neuropsychopharmacol"},{"key":"440_CR33","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1016\/j.biopsych.2005.10.020","volume":"59","author":"AC Leon","year":"2006","unstructured":"Leon AC, Mallinckrodt CH, Chuang-Stein C, Archibald DG, Archer GE, Chartier K. Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology. Biol Psychiatry. 2006;59:1001\u20135.","journal-title":"Biol Psychiatry"},{"key":"440_CR34","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.jclinepi.2005.06.006","volume":"59","author":"TA Furukawa","year":"2006","unstructured":"Furukawa TA, Barbui C, Cipriani A, Brambilla P, Watanabe N. Imputing missing standard deviations in meta-analyses can provide accurate results. J Clin Epidemiol. 2006;59:7\u201310.","journal-title":"J Clin Epidemiol"},{"key":"440_CR35","doi-asserted-by":"publisher","first-page":"4147","DOI":"10.1002\/sim.2689","volume":"25","author":"G Salanti","year":"2006","unstructured":"Salanti G, Higgins JP, White IR. Bayesian synthesis of epidemiological evidence with different combinations of exposure groups: application to a gene-gene-environment interaction. Stat Med. 2006;25:4147\u201363.","journal-title":"Stat Med"},{"key":"440_CR36","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1001\/jamapsychiatry.2014.2127","volume":"72","author":"TA Furukawa","year":"2015","unstructured":"Furukawa TA, Levine SZ, Tanaka S, Goldberg Y, Samara M, Davis JM, et al. Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies. JAMA Psychiatry. 2015;72:14\u201321.","journal-title":"JAMA Psychiatry"},{"key":"440_CR37","doi-asserted-by":"publisher","first-page":"e308","DOI":"10.4088\/JCP.13m08853","volume":"75","author":"J Rabinowitz","year":"2014","unstructured":"Rabinowitz J, Werbeloff N, Caers I, Mandel FS, Stauffer V, Menard F, et al. Determinants of antipsychotic response in schizophrenia: implications for practice and future clinical trials. J Clin Psychiatry. 2014;75:e308\u201316.","journal-title":"J Clin Psychiatry"},{"key":"440_CR38","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.1016\/j.euroneuro.2014.02.006","volume":"24","author":"T Mattila","year":"2014","unstructured":"Mattila T, Wohlfarth T, Koeter M, Storosum J, van den Brink W, de Haan L, et al. Geographic variation in efficacy of atypical antipsychotics for the acute treatment of schizophrenia-an individual patient data meta-analysis. Eur Neuropsychopharmacol: J Eur Coll Neuropsychopharmacol. 2014;24:1067\u201377.","journal-title":"Eur Neuropsychopharmacol: J Eur Coll Neuropsychopharmacol"},{"key":"440_CR39","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1093\/schbul\/sbn005","volume":"35","author":"J Rabinowitz","year":"2009","unstructured":"Rabinowitz J, Levine SZ, Barkai O, Davidov O. Dropout rates in randomized clinical trials of antipsychotics: a meta-analysis comparing first- and second-generation drugs and an examination of the role of trial design features. Schizophr Bull. 2009;35:775\u201388.","journal-title":"Schizophr Bull"},{"key":"440_CR40","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.schres.2015.02.021","volume":"164","author":"SZ Levine","year":"2015","unstructured":"Levine SZ, Goldberg Y, Samara M, Davis JM, Leucht S. Joint modeling of dropout and outcome in three pivotal clinical trials of schizophrenia. Schizophr Res. 2015;164:122\u20136.","journal-title":"Schizophr Res"},{"key":"440_CR41","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1001\/jama.1995.03520290060030","volume":"273","author":"KF Schulz","year":"1995","unstructured":"Schulz KF, Chalmers I, Hayes RJ, Altman DG. Empirical evidence of bias: dimensions of methodological quality associated with estimates of treatment effects in controlled trials. JAMA. 1995;273:408\u201312.","journal-title":"JAMA"},{"key":"440_CR42","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1136\/bmj.39465.451748.AD","volume":"336","author":"L Wood","year":"2008","unstructured":"Wood L, Egger M, Gluud LL, Schulz KF, Juni P, Altman DG, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study. BMJ. 2008;336:601\u20135.","journal-title":"BMJ"},{"key":"440_CR43","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.jclinepi.2006.09.013","volume":"60","author":"N Porta","year":"2007","unstructured":"Porta N, Bonet C, Cobo E. Discordance between reported intention-to-treat and per protocol analyses. J Clin Epidemiol. 2007;60:663\u20139.","journal-title":"J Clin Epidemiol"},{"key":"440_CR44","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey mG, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629\u201334.","journal-title":"BMJ"},{"key":"440_CR45","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1176\/appi.ajp.163.2.185","volume":"163","author":"S Heres","year":"2006","unstructured":"Heres S, Davis J, Maino K, Jetzinger E, Kissling W, Leucht S. Why olanzapine beats risperidone, risperidone beats quetiapine, and quetiapine beats olanzapine: an exploratory analysis of head-to-head comparison studies of second-generation antipsychotics. Am J Psychiatry. 2006;163:185\u201394.","journal-title":"Am J Psychiatry"},{"key":"440_CR46","doi-asserted-by":"publisher","first-page":"2318","DOI":"10.1016\/j.euroneuro.2015.08.019","volume":"25","author":"J Zohar","year":"2015","unstructured":"Zohar J, Stahl S, Moller HJ, Blier P, Kupfer D, Yamawaki S, et al. A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature. Eur Neuropsychopharmacol. 2015;25:2318\u201325.","journal-title":"Eur Neuropsychopharmacol"},{"key":"440_CR47","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1176\/appi.ajp.2009.09060802","volume":"167","author":"DM Gardner","year":"2010","unstructured":"Gardner DM, Murphy AL, O\u2019Donnell H, Centorrino F, Baldessarini RJ. International consensus study of antipsychotic dosing. Am J Psychiatry. 2010;167:686\u201393.","journal-title":"Am J Psychiatry"},{"key":"440_CR48","doi-asserted-by":"publisher","first-page":"2982","DOI":"10.1002\/sim.2768","volume":"26","author":"MC Simmonds","year":"2007","unstructured":"Simmonds MC, Higgin JP. Covariate heterogeneity in meta-analysis: criteria for deciding between meta-regression and individual patient data. Stat Med. 2007;26:2982\u201399.","journal-title":"Stat Med"},{"issue":"1","key":"440_CR49","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1097\/JGP.0b013e31815a3e7a","volume":"16","author":"Andreas Tzimos","year":"2008","unstructured":"Tzimos A, Samokhvalov V, Kramer M, Ford L, Gassmann-Mayer C, Lim P, et al. Safety and Tolerability of Oral Paliperidone Extended-Release Tablets in Elderly Patients With Schizophrenia: A Double-Blind, Placebo-Controlled Study With Six-Month Open-Label Extension Am J Geriatr Psychiatry. 2008;16:31\u201343.","journal-title":"The American Journal of Geriatric Psychiatry"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41386-019-0440-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41386-019-0440-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41386-019-0440-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:06:41Z","timestamp":1684616801000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41386-019-0440-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,18]]},"references-count":49,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["440"],"URL":"https:\/\/doi.org\/10.1038\/s41386-019-0440-6","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,18]]},"assertion":[{"value":"30 January 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 June 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}